Top

Published in:

01-11-2013 | Review

Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor

Author: Francisco J. Quintana

Published in: Seminars in Immunopathology | Issue 6/2013

Abstract

The ligand-activated transcription factor aryl hydrocarbon receptor controls the activity of several components of the immune system, many of which play an important role in neuroinflammation. This review discusses the role of AhR in T cells and dendritic cells, its relevance for the control of autoimmunity in the central nervous system, and its potential as a therapeutic target for immune-mediated disorders.

Nylander A, Hafler DA (2012) Multiple sclerosis. J Clin Invest 122(4):1180–1188. doi:10.1172/jci58649 PubMed

Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB (2002) T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 20:101–123PubMed

Steinman L, Zamvil SS (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60(1):12–21. doi:10.1002/ana.20913 PubMed

Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517. doi:10.1146/annurev.immunol.021908.132710 PubMed

Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361(9):888–898. doi:10.1056/NEJMra0707449 PubMed

Pot C, Apetoh L, Kuchroo VK (2011) Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol 23(3):202–208. doi:10.1016/j.smim.2011.07.005 PubMed

Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10(7):490–500. doi:10.1038/nri2785 PubMed

Bailey SL, Schreiner B, Mcmahon EJ, Miller SD (2007) CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ TH-17 cells in relapsing EAE. Nat Immunol 8(2):172–180. doi:10.1038/ni1430 PubMed

Yogev N, Frommer F, Lukas D, Kautz-Neu K, Karram K, Ielo D, Von Stebut E, Probst H-C, van den Broek M, Riethmacher D, Birnberg T, Blank T, Reizis B, Korn T, Wiendl H, Jung S, Prinz M, Kurschus FC, Waisman A (2012) Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor + regulatory T cells. Immunity 37(2):264–275. doi:10.1016/j.immuni.2012.05.025 PubMed

10.

Nguyen LP, Bradfield CA (2008) The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 21(1):102–116. doi:10.1021/tx7001965 PubMed

11.

McIntosh BE, Hogenesch JB, Bradfield CA (2010) Mammalian Per-Arnt-Sim proteins in environmental adaptation. Annu Rev Physiol 72:625–645. doi:10.1146/annurev-physiol-021909-135922 PubMed

12.

Dere E, Lo R, Celius T, Matthews J, Zacharewski TR (2011) Integration of genome-wide computation DRE search, AhR ChIP-chip and gene expression analyses of TCDD-elicited responses in the mouse liver. BMC Genomics 12:365. doi:10.1186/1471-2164-12-365 PubMed

13.

Kinehara M, Fukuda I, Yoshida K, Ashida H (2008) High-throughput evaluation of aryl hydrocarbon receptor-binding sites selected via chromatin immunoprecipitation-based screening in Hepa-1c1c7 cells stimulated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Genes Genet Syst 83(6):455–468PubMed

14.

Lo R, Matthews J (2012) High-resolution genome-wide mapping of AHR and ARNT binding sites by ChIP-Seq. Toxicol Sci 130(2):349–361. doi:10.1093/toxsci/kfs253 PubMed

15.

Boronat S, Casado S, Navas JM, Pina B (2007) Modulation of aryl hydrocarbon receptor transactivation by carbaryl, a nonconventional ligand. FEBS J 274(13):3327–3339. doi:10.1111/j.1742-4658.2007.05867.x PubMed

16.

Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro CR, Gowdahalli K, Amin SG, Perdew GH (2010) Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. Mol Pharmacol 77(2):247–254. doi:10.1124/mol.109.061788 PubMed

17.

Zhang S, Rowlands C, Safe S (2008) Ligand-dependent interactions of the Ah receptor with coactivators in a mammalian two-hybrid assay. Toxicol Appl Pharmacol 227(2):196–206. doi:10.1016/j.taap.2007.10.019 PubMed

18.

Matsumura F (2009) The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects. Biochem Pharmacol 77(4):608–626. doi:10.1016/j.bcp.2008.10.013 PubMed

19.

Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, Kouzmenko A, Nohara K, Chiba T, Fujii-Kuriyama Y, Kato S (2007) Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446(7135):562–566. doi:10.1038/nature05683 PubMed

20.

Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268(5211):722–726PubMed

21.

Temchura VV, Frericks M, Nacken W, Esser C (2005) Role of the aryl hydrocarbon receptor in thymocyte emigration in vivo. Eur J Immunol 35(9):2738–2747. doi:10.1002/eji.200425641 PubMed

22.

Denison MS, Nagy SR (2003) Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309–334, Epub 2002 Jan 2010PubMed

23.

Denison MS, Pandini A, Nagy SR, Baldwin EP, Bonati L (2002) Ligand binding and activation of the Ah receptor. Chem Biol Interact 141(1–2):3–24PubMed

24.

Chowdhury G, Dostalek M, Hsu EL, Nguyen LP, Stec DF, Bradfield CA, Guengerich FP (2009) Structural identification of diindole agonists of the aryl hydrocarbon receptor derived from degradation of indole-3-pyruvic acid. Chem Res Toxicol 22(12):1905–1912. doi:10.1021/tx9000418 PubMed

25.

Nguyen LP, Hsu EL, Chowdhury G, Dostalek M, Guengerich FP, Bradfield CA (2009) D-amino acid oxidase generates agonists of the aryl hydrocarbon receptor from D-tryptophan. Chem Res Toxicol 22(12):1897–1904. doi:10.1021/tx900043s PubMed

26.

Wei YD, Helleberg H, Rannug U, Rannug A (1998) Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole. Chem Biol Interact 110(1–2):39–55PubMed

27.

Song J, Clagett-Dame M, Peterson RE, Hahn ME, Westler WM, Sicinski RR, DeLuca HF (2002) A ligand for the aryl hydrocarbon receptor isolated from lung. Proc Natl Acad Sci U S A 99(23):14694–14699, Epub 12002 Oct 14630PubMed

28.

Heath-Pagliuso S, Rogers WJ, Tullis K, Seidel SD, Cenijn PH, Brouwer A, Denison MS (1998) Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 37(33):11508–11515PubMed

29.

Henry EC, Bemis JC, Henry O, Kende AS, Gasiewicz TA (2006) A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch Biochem Biophys 450(1):67–77PubMed

30.

Moffett JR, Namboodiri MA (2003) Tryptophan and the immune response. Immunol Cell Biol 81(4):247–265. doi:10.1046/j.1440-1711.2003.t01-1-01177.x PubMed

31.

Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I (2005) Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 19(10):1347–1349. doi:10.1096/fj.04-3228fje PubMed

32.

Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310(5749):850–855. doi:10.1126/science.1117634 PubMed

33.

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197–203. doi:10.1038/nature10491 PubMed

34.

Takamura T, Harama D, Fukumoto S, Nakamura Y, Shimokawa N, Ishimaru K, Ikegami S, Makino S, Kitamura M, Nakao A (2011) Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. Immunol Cell Biol 89(7):817–822. doi:10.1038/icb.2010.165 PubMed

35.

Zelenay S, Bergman M-L, Paiva RS, Lino AC, Martins AC, Duarte JH, Moraes-Fontes MF, Bilate AM, Lafaille JJ, Demengeot J (2010) Cutting edge: intrathymic differentiation of adaptive Foxp3+ regulatory T cells upon peripheral proinflammatory immunization. J Immunol 185(7):3829–3833. doi:10.4049/jimmunol.1001281 PubMed

36.

Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Backstrom BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13(4):423–431. doi:10.1038/nm1564 PubMed

37.

Benson JM, Shepherd DM (2011) Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol Sci 124(2):327–338. doi:10.1093/toxsci/kfr249 PubMed

38.

Benson JM, Shepherd DM (2011) Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn’s disease. Toxicol Sci 120(1):68–78. doi:10.1093/toxsci/kfq360 PubMed

39.

Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, Mourich DV (2009) Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 1(4):539–547PubMed

40.

Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 23:23

41.

Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ, Weiner HL (2010) An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107(48):20768–20773. doi:10.1073/pnas.1009201107 PubMed

42.

Wang HK, Yeh CH, Iwamoto T, Satsu H, Shimizu M, Totsuka M (2012) Dietary flavonoid naringenin induces regulatory T cells via an aryl hydrocarbon receptor mediated pathway. J Agric Food Chem 60(9):2171–2178. doi:10.1021/jf204625y PubMed

43.

Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ (2012) Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 109(28):11270–11275. doi:10.1073/pnas.1120611109 PubMed

44.

Singh NP, Singh UP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS (2011) Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS One 6(8):e23522. doi:10.1371/journal.pone.0023522 PubMed

45.

Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11(9):846–853. doi:10.1038/ni.1915 PubMed

46.

Caretto D, Katzman SD, Villarino AV, Gallo E, Abbas AK (2010) Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol 184(1):30–34. doi:10.4049/jimmunol.0903412 PubMed

47.

Kimura A, Naka T, Kishimoto T (2007) IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A 104(29):12099–12104. doi:10.1073/pnas.0705268104 PubMed

48.

Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Mart Iacute Nez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA (2009) Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10(9):1000–1007. doi:10.1038/ni.1774 PubMed

49.

Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531–564. doi:10.1146/annurev.immunol.25.022106.141623 PubMed

50.

Bettini ML, Pan F, Bettini M, Finkelstein D, Rehg JE, Floess S, Bell BD, Ziegler SF, Huehn J, Pardoll DM, Vignali DA (2012) Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity 36(5):717–730. doi:10.1016/j.immuni.2012.03.020 PubMed

51.

Fu W, Ergun A, Lu T, Hill JA, Haxhinasto S, Fassett MS, Gazit R, Adoro S, Glimcher L, Chan S, Kastner P, Rossi D, Collins JJ, Mathis D, Benoist C (2012) A multiply redundant genetic switch ‘locks in’ the transcriptional signature of regulatory T cells. Nat Immunol 13(10):972–980. doi:10.1038/ni.2420 PubMed

52.

Pan F, Yu H, Dang EV, Barbi J, Pan X, Grosso JF, Jinasena D, Sharma SM, McCadden EM, Getnet D, Drake CG, Liu JO, Ostrowski MC, Pardoll DM (2009) Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 325(5944):1142–1146. doi:10.1126/science.1176077 PubMed

53.

Gottschalk RA, Corse E, Allison JP (2012) Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 188(3):976–980. doi:10.4049/jimmunol.1102964 PubMed

54.

Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM (2010) Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184(7):3433–3441. doi:10.4049/jimmunol.0904028 PubMed

55.

Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, Seavitt J, Georgopoulos K, Kuchroo VK (2012) Aiolos promotes T(H)17 differentiation by directly silencing Il2 expression. Nat Immunol 13(8):770–777. doi:10.1038/ni.2363 PubMed

56.

Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326(5955):986–991. doi:10.1126/science.1172702 PubMed

57.

Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY (2009) Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458(7236):351–356. doi:10.1038/nature07674 PubMed

58.

Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652):737–742. doi:10.1038/39614 PubMed

59.

Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50. doi:10.1111/j.0105-2896.2006.00420.x PubMed

60.

Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10 (3):170–181. doi:10.1038/nri2711

61.

Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380–1389. doi:10.1038/ni1541 PubMed

62.

Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, Saris CJ, Gran B, Ciric B, Rostami A (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 8(12):1372–1379. doi:10.1038/ni1540 PubMed

63.

Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O’Shea JJ, Hunter CA (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8(12):1363–1371. doi:10.1038/ni1537 PubMed

64.

Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765. doi:10.1146/annurev.immunol.19.1.683 PubMed

65.

Astier AL, Meiffren G, Freeman S, Hafler DA (2006) Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 116(12):3252–3257. doi:10.1172/jci29251 PubMed

66.

Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK (1998) IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 161(7):3299–3306PubMed

67.

Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O’Garra A (2009) Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31(2):209–219. doi:10.1016/j.immuni.2009.05.012 PubMed

68.

Marshall NB, Vorachek WR, Steppan LB, Mourich DV, Kerkvliet NI (2008) Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol 181(4):2382–2391PubMed

69.

Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11(9):854–861. doi:10.1038/ni.1912 PubMed

70.

Wu HY, Quintana FJ, da Cunha AP, Dake BT, Koeglsperger T, Starossom SC, Weiner HL (2011) In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS One 6(8):e23618. doi:10.1371/journal.pone.0023618 PubMed

71.

Xu J, Yang Y, Qiu G, Lal G, Wu Z, Levy DE, Ochando JC, Bromberg JS, Ding Y (2009) c-Maf regulates IL-10 expression during Th17 polarization. J Immunol 182(10):6226–6236. doi:10.4049/jimmunol.0900123 PubMed

72.

Umetsu SE, Winandy S (2009) Ikaros is a regulator of Il10 expression in CD4+ T cells. J Immunol 183(9):5518–5525. doi:10.4049/jimmunol.0901284 PubMed

73.

Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC, Kuchroo VK (2009) Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 183(2):797–801. doi:10.4049/jimmunol.0901233 PubMed

74.

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126(6):1121–1133. doi:10.1016/j.cell.2006.07.035 PubMed

75.

Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM, Dong C (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28(1):29–39. doi:10.1016/j.immuni.2007.11.016 PubMed

76.

Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR (2011) Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 472(7344):486–490. doi:10.1038/nature09978 PubMed

77.

Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovic D, Schurer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472(7344):491–494. doi:10.1038/nature10075 PubMed

78.

Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191):65–72. doi:10.1038/nature06880 PubMed

79.

Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 105(28):9721–9726. doi:10.1073/pnas.0804231105 PubMed

80.

Veldhoen M, Hirota K, Westendorf A, Buer J, Dumoutier L, Renauld J, Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453(7191):106–109. doi:10.1038/nature06881 PubMed

81.

Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206(1):43–49. doi:10.1084/jem.20081438 PubMed

82.

Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, Agarwal A, Huang W, Parkurst CN, Muratet M, Newberry KM, Meadows S, Greenfield A, Yang Y, Jain P, Kirigin FK, Birchmeier C, Wagner EF, Murphy KM, Myers RM, Bonneau R, Littman DR (2012) A validated regulatory network for Th17 cell specification. Cell 151(2):289–303. doi:10.1016/j.cell.2012.09.016 PubMed

83.

Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, Gennert D, Satija R, Shakya A, Lu DY, Trombetta JJ, Pillai MR, Ratcliffe PJ, Coleman ML, Bix M, Tantin D, Park H, Kuchroo VK, Regev A (2013) Dynamic regulatory network controlling T17 cell differentiation. Nature. doi:10.1038/nature11981

84.

Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, Shevach EM, O’Shea JJ (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3):371–381. doi:10.1016/j.immuni.2007.02.009 PubMed

85.

Liao W, Lin JX, Wang L, Li P, Leonard WJ (2011) Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 12(6):551–559. doi:10.1038/ni.2030 PubMed

86.

Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, Kanno Y, O’Shea JJ, Laurence A (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12(3):247–254. doi:10.1038/ni.1995 PubMed

87.

Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, Sobel RA, Regev A, Kuchroo VK (2012) Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13(10):991–999. doi:10.1038/ni.2416 PubMed

88.

McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390–1397. doi:10.1038/ni1539 PubMed

89.

Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448(7152):484–487. doi:10.1038/nature05970 PubMed

90.

Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448(7152):480–483. doi:10.1038/nature05969 PubMed

91.

Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449(7161):419–426. doi:10.1038/nature06175 PubMed

92.

Comabella M, Montalban X, Münz C, Lünemann JD (2010) Targeting dendritic cells to treat multiple sclerosis. Nat Rev Neurol 6(9):499–507. doi:10.1038/nrneurol.2010.112 PubMed

93.

Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11(3):328–334. doi:10.1038/nm1197 PubMed

94.

Bailey-Bucktrout SL, Caulkins SC, Goings G, Fischer JAA, Dzionek A, Miller SD (2008) Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J Immunol 180(10):6457–6461PubMed

95.

Mcmahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11(3):335–339. doi:10.1038/nm1202 PubMed

96.

Gillesby BE, Stanostefano M, Porter W, Safe S, Wu ZF, Zacharewski TR (1997) Identification of a motif within the 5′ regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. Biochemistry 36(20):6080–6089. doi:10.1021/bi962131b PubMed

97.

Tian Y, Ke S, Denison MS, Rabson AB, Gallo MA (1999) Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274(1):510–515PubMed

98.

Amit I, Garber M, Chevrier N, Leite AP, Donner Y, Eisenhaure T, Guttman M, Grenier JK, Li W, Zuk O, Schubert LA, Birditt B, Shay T, Goren A, Zhang X, Smith Z, Deering R, McDonald RC, Cabili M, Bernstein BE, Rinn JL, Meissner A, Root DE, Hacohen N, Regev A (2009) Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 326(5950):257–263. doi:10.1126/science.1179050 PubMed

99.

Garber M, Yosef N, Goren A, Raychowdhury R, Thielke A, Guttman M, Robinson J, Minie B, Chevrier N, Itzhaki Z, Blecher-Gonen R, Bornstein C, Amann-Zalcenstein D, Weiner A, Friedrich D, Meldrim J, Ram O, Cheng C, Gnirke A, Fisher S, Friedman N, Wong B, Bernstein BE, Nusbaum C, Hacohen N, Regev A, Amit I (2012) A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol Cell 47(5):810–822. doi:10.1016/j.molcel.2012.07.030 PubMed

100.

Hauben E, Gregori S, Draghici E, Migliavacca B, Olivieri S, Woisetschlager M, Roncarolo MG (2008) Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 112(4):1214–1222. doi:10.1182/blood-2007-08-109843 PubMed

101.

Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190–3198. doi:10.4049/jimmunol.0903670 PubMed

102.

Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2010) Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 107(46):19961–19966. doi:10.1073/pnas.1014465107 PubMed

103.

Simones T, Shepherd DM (2011) Consequences of AhR activation in steady-state dendritic cells. Toxicol Sci 119(2):293–307. doi:10.1093/toxsci/kfq354 PubMed

104.

Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F (2008) Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 375(3):331–335. doi:10.1016/j.bbrc.2008.07.156 PubMed

105.

Hall JA, Grainger JR, Spencer SP, Belkaid Y (2011) The role of retinoic acid in tolerance and immunity. Immunity 35(1):13–22. doi:10.1016/j.immuni.2011.07.002 PubMed

106.

Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2009) Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 206(9):2027–2035. doi:10.1084/jem.20090560 PubMed

107.

Sekine H, Mimura J, Oshima M, Okawa H, Kanno J, Igarashi K, Gonzalez FJ, Ikuta T, Kawajiri K, Fujii-Kuriyama Y (2009) Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-induced septic shock. Mol Cell Biol 29(24):6391–6400. doi:10.1128/mcb.00337-09 PubMed

108.

Sanvicens N, Marco MP (2008) Multifunctional nanoparticles—properties and prospects for their use in human medicine. Trends Biotechnol 26(8):425–433PubMed

Title: Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor
Author: Francisco J. Quintana
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Seminars in Immunopathology / Issue 6/2013
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-013-0397-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

The role of the aryl hydrocarbon receptor in normal and malignant B cell development

The aryl hydrocarbon receptor in innate T cell immunity

Aryl hydrocarbon receptor and experimental autoimmune arthritis

Aryl hydrocarbon receptor and colitis

Fine tuning of the immune response by the Aryl Hydrocarbon Receptor

Functions of the aryl hydrocarbon receptor in the skin

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage